Lumos Pharma to Participate in December Investor Conferences
23 nov. 2020 19h43 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company...
Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results
10 nov. 2020 16h01 HE
|
Lumos Pharma, Inc.
Lumos Pharma has initiated Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency (PGHD) patients with data read-out anticipated mid-year 2022 AUSTIN, Texas, Nov. ...
Lumos Pharma to Participate in November Investor Conferences
29 oct. 2020 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company...
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
27 oct. 2020 16h01 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Lumos Pharma to Participate in Upcoming Investor Conferences
27 août 2020 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company...
Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
13 août 2020 16h01 HE
|
Lumos Pharma, Inc.
Lumos Pharma sells Priority Review Voucher (PRV), valued at $100 million - Lumos Pharma to receive $60 million for its 60% interest in PRVLumos Pharma reaffirms its expectation of the initiation of...
Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020
28 juil. 2020 16h01 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Lumos Pharma Announces Sale of Priority Review Voucher
27 juil. 2020 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has...
Lumos Pharma Reports First Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
28 mai 2020 16h01 HE
|
Lumos Pharma, Inc.
- Lumos Pharma expects to initiate its Phase 2b LUM-201 trial in Pediatric Growth Hormone Deficiency (PGHD) prior to the end of 2020 - Additional non-dilutive funds expected from anticipated...
Lumos Pharma to Participate in the Jefferies 2020 Healthcare Conference
27 mai 2020 16h27 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the...